Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Teva Pharmaceutical Industries Ltd (ADR) : Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Mylan

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 02:22pm CEST

NEW YORK, NY / ACCESSWIRE / October 5, 2017 / Traders had a big reason to celebrate Mylan on Wednesday after the drug's generic version of Teva's Copaxone was approved by the FDA. Generic competition for Teva's drug wasn't expected until at least 2018 so this was an early surprise. While shares of Mylan rose higher on the news, Teva's shares sank as investors grew concerned over the new competition.

RDI Initiates Coverage on:

Teva Pharmaceutical Industries Limited

Mylan N.V.

Teva Pharmaceutical Industries Limited's shares fell 14.56% on Wednesday with nearly 80 million shares traded. It was a gloomy day for the stock after a generic version of its MS drug Copaxone was approved by the FDA. Copaxone is Teva's blockbuster branded drug. Jefferies analyst David Steinberg wrote, "We note, the ongoing challenges to its generics business and that with FDA approval of Mylan's generic of Copaxone, earnings/cash flow are likely to [be] affected." The approval for Mylan's drug came earlier than either company had expected. There were two different doses of Mylan's version of the drug, 20 mg and 40 mg, which were approved by the FDA. The fact that the 40 mg dosage represented over 85 percent of Teva's Copaxone prescriptions in the second quarter didn't make the news yesterday any easier for Teva traders.

Access RDI's Teva Pharmaceutical Industries Limited Research Report at:

Mylan N.V.'s shares closed up 16.20% on Wednesday with nearly 37 million shares traded. The stock sprang to life after the Food & Drug Administration approved the company's generic multiple sclerosis drug, Glatiramer Acetate. The drug is a generic version of Teva Pharmaceutical's multiple sclerosis treatment Copaxone. The company said it would begin shipping Glatiramer Acetate 40 mg/mL for 3-times-a-week injection and 20 mg/mL for once-daily injection immediately. While traders celebrated the news, Wells Fargo Securities senior analyst David Maris called the breakout "a little bit exaggerated" when speaking to CNBC. According to Maris, the generic Copaxone 40 mg could contribute about $0.13 in earnings per share per quarter. He wrote in a note however that "it may be unrealistic to assume a quick share shift given the patient population and the nature of the disease. It will bear close watching whether the market converts to a new player, or like in the case of the 20 mg, Teva is able to maintain a good amount of share." Copaxone made $4 billion for Teva in 2016.

Access RDI's Mylan N.V. Research Report at:

Our Actionable Research on Teva Pharmaceutical Industries Limited (NYSE: TEVA) and Mylan N.V. (NASDAQ: MYL) be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.


For any questions, inquiries, or comments reach out to us directly at:


Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011


[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

© Accesswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
07/20TEVA PHARMACEUTICAL INDUSTRIES : Highlights Key Milestones Achieved in the 2017 ..
07/19TEVA PHARMACEUTICAL INDUSTRIES : Announces Launch of a Generic Version of Uceris..
07/19TEVA PHARMACEUTICAL INDUSTRIES : Court allows closure of Teva's Ashdod plant
07/17PAXMAN PUBL : receives first order from Teva in Mexico for 17 scalp cooling syst..
07/17TEVA PHARMACEUTICAL INDUSTRIES : Highlights Key Milestones Achieved in the 2017 ..
07/16TEVA PHARMACEUTICAL INDUSTRIES : Previous ArticleTeva Reports First Quarter 2018..
07/13TEVA PHARMACEUTICAL INDUSTRIES : FDA Recalls Several Medicines That Contain Vals..
07/13TEVA PHARMACEUTICAL INDUSTRIES : to Report Second Quarter 2018 Financial Results..
07/12TEVA PHARMACEUTICAL INDUSTRIES : Researchers at Teva Pharmaceutical Report New D..
07/12TEVA PHARMACEUTICAL INDUSTRIES : Mylan generic Copaxone price cut puzzles indust..
More news
News from SeekingAlpha
07/11YOUR DAILY PHARMA SCOOP : IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish 
07/11Big Pharma in the red after Pfizer backs away from price hikes 
07/10Pricing transparency law in California having effect, drug makers nix planned.. 
07/10Crinetics Pharmaceuticals Readies $80 Million IPO 
07/09Biotechs give up gains after Trump tweet on prices 
Financials ($)
Sales 2018 19 600 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 1,20x
Capi. / Sales 2019 1,20x
Capitalization 23 487 M
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 19,5 $
Spread / Average Target -16%
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-9.93%342 779
PFIZER3.06%220 295
NOVARTIS-1.75%206 001
ROCHE HOLDING LTD.-5.90%203 399
MERCK AND COMPANY11.11%169 328